CAZypedia needs your help! We have many unassigned GH, PL, CE, AA, GT, and CBM pages in need of Authors and Responsible Curators.
Scientists at all career stages, including students, are welcome to contribute to CAZypedia. Read more here, and in the 10th anniversary article in Glycobiology.
New to the CAZy classification? Read this first.
*
Consider attending the 15th Carbohydrate Bioengineering Meeting in Ghent, 5-8 May 2024.

Difference between revisions of "Carbohydrate Binding Module Family 94"

From CAZypedia
Jump to navigation Jump to search
Line 17: Line 17:
  
 
== Ligand specificities ==
 
== Ligand specificities ==
Mention here all major natural ligand specificities that are found within a given family (also plant or mammalian origin). Certain linkages and promiscuity would also be mentioned here if biologically relevant.
+
CBM94 was established in 2022 after the structural and functional characterization of the C-terminal domains of human ''N''-acetylglucosaminyltransferase IVa (GnT-IVa, MGAT4A; [[GT54]]; EC 2.4.1.145) and an ortholog from lepidopteran insect ''Bombyx mori'' <cite>Oka2022</cite>. The CBM94 proteins from human and ''B. mori'' comprise of around 140 amino acid residues and showed affinity toward ''N''-acetylglucosamine, ''N'',''N''’-diacetylchitobiose, and ''p''-nitrophenyl β-''N''-acetylglucosaminide with ''K''<sub>a</sub> values of 242–1,970 M<sup>−1</sup>. No affinity was detected for other monosaccharides, including glucose, mannose, galactose, L-fucose, and ''N''-acetylgalactosamine, some of which are components of matured ''N''-glycans <cite>Oka2022</cite>. Nagae et al. demonstrated that the C-terminal domain of mouse GnT-IVa has binding ability for GlcNAc and GlcNAcβ1-2Man using NMR titration analysis <cite>Nagae2022</cite>. Furthermore, comprehensive frontal affinity chromatography analysis using 157 glycans showed that mouse CBM94 has affinity for ''N''-glycans with β-(1→2) and β-(1→4)-linked GlcNAc at the non-reducing ends. On the other hand, it showed low affinity for ''N''-glycan with only β-(1→2)-linked GlcNAc, which is the substrate of GnT-IV <cite>Nagae2022</cite>. Therefore, CBM94 prefers product ''N''-glycans rather than substrate ''N''-glycans.
 
 
''Note: Here is an example of how to insert references in the text, together with the "biblio" section below:'' Please see these references for an essential introduction to the CAZy classification system: <cite>DaviesSinnott2008 Cantarel2009</cite>. CBMs, in particular, have been extensively reviewed <cite>Boraston2004 Hashimoto2006 Shoseyov2006 Guillen2010 Armenta2017</cite>.
 
  
 
== Structural Features ==
 
== Structural Features ==
Line 43: Line 41:
 
#Oka2022 pmid=36106687
 
#Oka2022 pmid=36106687
 
#Nagae2022 pmid=35854001
 
#Nagae2022 pmid=35854001
 
 
#Osada2022 pmid=35988645
 
#Osada2022 pmid=35988645
  

Revision as of 20:20, 19 January 2023

Under construction icon-blue-48px.png

This page is currently under construction. This means that the Responsible Curator has deemed that the page's content is not quite up to CAZypedia's standards for full public consumption. All information should be considered to be under revision and may be subject to major changes.


CAZy DB link
http://www.cazy.org/CBM94.html

Ligand specificities

CBM94 was established in 2022 after the structural and functional characterization of the C-terminal domains of human N-acetylglucosaminyltransferase IVa (GnT-IVa, MGAT4A; GT54; EC 2.4.1.145) and an ortholog from lepidopteran insect Bombyx mori [1]. The CBM94 proteins from human and B. mori comprise of around 140 amino acid residues and showed affinity toward N-acetylglucosamine, N,N’-diacetylchitobiose, and p-nitrophenyl β-N-acetylglucosaminide with Ka values of 242–1,970 M−1. No affinity was detected for other monosaccharides, including glucose, mannose, galactose, L-fucose, and N-acetylgalactosamine, some of which are components of matured N-glycans [1]. Nagae et al. demonstrated that the C-terminal domain of mouse GnT-IVa has binding ability for GlcNAc and GlcNAcβ1-2Man using NMR titration analysis [2]. Furthermore, comprehensive frontal affinity chromatography analysis using 157 glycans showed that mouse CBM94 has affinity for N-glycans with β-(1→2) and β-(1→4)-linked GlcNAc at the non-reducing ends. On the other hand, it showed low affinity for N-glycan with only β-(1→2)-linked GlcNAc, which is the substrate of GnT-IV [2]. Therefore, CBM94 prefers product N-glycans rather than substrate N-glycans.

Structural Features

Content in this section should include, in paragraph form, a description of:

  • Fold: Structural fold (beta trefoil, beta sandwich, etc.)
  • Type: Include here Type A, B, or C and properties
  • Features of ligand binding: Describe CBM binding pocket location (Side or apex) important residues for binding (W, Y, F, subsites), interact with reducing end, non-reducing end, planar surface or within polysaccharide chains. Include examples pdb codes. Metal ion dependent. Etc.

Functionalities

Content in this section should include, in paragraph form, a description of:

  • Functional role of CBM: Describe common functional roles such as targeting, disruptive, anchoring, proximity/position on substrate.
  • Most Common Associated Modules: 1. Glycoside Hydrolase Activity; 2. Additional Associated Modules (other CBM, FNIII, cohesin, dockerins, expansins, etc.)
  • Novel Applications: Include here if CBM has been used to modify another enzyme, or if a CBM was used to label plant/mammalian tissues? Etc.

Family Firsts

First Identified
Sugar-binding ability of the C-terminal domains of human and mouse GnT-IVa (MGAT4A) and Bombyx mori ortholog was identified independently by two groups [1, 2].
First Structural Characterization
Crystal structures of the C-terminal domains of human and mouse GnT-IVa (MGAT4A) and Bombyx mori ortholog were determined independently by two groups [1, 2]. β-GlcNAc-bound structure of B. mori CBM94 was also determined [1].

References

  1. Oka N, Mori S, Ikegaya M, Park EY, and Miyazaki T. (2022). Crystal structure and sugar-binding ability of the C-terminal domain of N-acetylglucosaminyltransferase IV establish a new carbohydrate-binding module family. Glycobiology. 2022;32(12):1153-1163. DOI:10.1093/glycob/cwac058 | PubMed ID:36106687 [Oka2022]
  2. Nagae M, Hirata T, Tateno H, Mishra SK, Manabe N, Osada N, Tokoro Y, Yamaguchi Y, Doerksen RJ, Shimizu T, and Kizuka Y. (2022). Discovery of a lectin domain that regulates enzyme activity in mouse N-acetylglucosaminyltransferase-IVa (MGAT4A). Commun Biol. 2022;5(1):695. DOI:10.1038/s42003-022-03661-w | PubMed ID:35854001 [Nagae2022]
  3. Osada N, Nagae M, Nakano M, Hirata T, and Kizuka Y. (2022). Examination of differential glycoprotein preferences of N-acetylglucosaminyltransferase-IV isozymes a and b. J Biol Chem. 2022;298(9):102400. DOI:10.1016/j.jbc.2022.102400 | PubMed ID:35988645 [Osada2022]

All Medline abstracts: PubMed